Navigation Links
Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
Date:11/24/2008

el and selective adenosine2a receptor antagonist for Parkinson's disease (completing Phase II); results of a Phase II dose-finding trial in patients suffering from moderate to severe Parkinson's disease were reported showing that preladenant met the primary endpoint.

Presenters reviewed a range of other therapies in various stages of development in the company's six therapeutic areas: allergy/respiratory; cardiovascular/metabolic; central nervous system; immunology/infectious disease; oncology; and women's health.

Several earlier-stage research projects were also unveiled for the first time, including:

  • Two monoclonal antibodies for oncology -- robatumumab (anti-IGF-1R) in Phase II and anti-HGF in Phase I;
  • Two projects for Alzheimer's -- a beta secretase inhibitor and a gamma secretase inhibitor; and
  • A novel anti-inflammatory agent, anti-IL-23, in Phase I for chronic inflammatory conditions.

In Animal Health, the company highlighted its global leadership position and diverse portfolio and pipeline, with more than 120 small-molecule projects and 140 biological projects under way. The company also highlighted three growth corridors for Schering-Plough: companion animal; parasiticides; and geographic expansion in the U.S., Japan and emerging markets.

Webcast Information

A replay of the webcast of Schering-Plough's "R&D Update" meeting is available by going to the Investor Relations section of the Schering-Plough corporate Web site, www.schering-plough.com, and clicking on the "Presentations/Webcasts" link. The replay will be available starting on Nov. 24 through 5 p.m. on Dec. 24.

Disclosure Notice

DISCLOSURE NOTICE:
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
2. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
3. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
4. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
5. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
6. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
7. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
8. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
11. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... -- CVS Caremark Corporation (NYSE: CVS ) announced ... payable in connection with its previously announced cash tender offers ... any and all of its 6.250% Senior Notes due 2027 ... maximum amount of its 6.125% Senior Notes due 2039, 5.750% ... (collectively, the "Maximum Tender Offer Notes" and together with the ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Bedrocan Cannabis ... three independent members to its Board of Directors, ... experience of the company, a leading licensed producer ... . Internationally, Bedrocan has 13 years, experience in ... in seven countries, including Canada. ...
(Date:8/21/2014)... 2014  SI-BONE, Inc. ( San Jose, California ... use of the iFuse Implant System, ® a ... the sacroiliac (SI) joint, announced that Priority Health ( ... Lumbar Fusion Medical Policy No. 91590-R4 providing positive coverage ... states that the fusion procedure, which employs the iFuse ...
Breaking Medicine Technology:CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3
... 29, 2011  Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased ... in 2012 through the development and sales of its ... management of medical conditions. In 2011, Solos Endoscopy consummated ... in debt for the Company. The signed settlement agreement ...
... Today, Zacks Equity Research discusses the Pharma & Biotech, ... Human Genome Sciences Inc. (Nasdaq: HGSI ... and Perrigo Company (Nasdaq: PRGO ). ... synopsis of today,s Industry Outlook is presented below. The ...
Cached Medicine Technology:Solos Endoscopy, Inc. is Primed for Growth in 2012 2Solos Endoscopy, Inc. is Primed for Growth in 2012 3Zacks Industry Outlook Highlights: Vertex Pharma, Human Genome Sciences, Biogen Idec and Perrigo 2Zacks Industry Outlook Highlights: Vertex Pharma, Human Genome Sciences, Biogen Idec and Perrigo 3Zacks Industry Outlook Highlights: Vertex Pharma, Human Genome Sciences, Biogen Idec and Perrigo 4
(Date:8/22/2014)... August 22, 2014 Dealing with a drug ... when the addict is a child. Adolescent substance abuse has ... a long time. But a new helpline is now providing ... professional youth rehab for something like a teen drug ... designed to help make a positive impact in the community. ...
(Date:8/22/2014)... August 22, 2014 According to ... System and Adaptive Cruise Control (ACC) System Market ... Forecasts 2014 - 2019", published by MarketsandMarkets, classifies ... Market in terms of volume and value. The ... years as well as covers review of the ...
(Date:8/21/2014)... August 22, 2014 The natural loss of ... lines, wrinkles and sagging of skin. Using products to ... age 40, the body has lost about 15% of it ... 45%," says Kathy Heshelow, founder of Sublime Beauty®. "Collagen ... it - well, we know what happens." , Collagen in ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Local agencies ... have larger discounts for specific protection plans, according to ... helping consumers to quote life insurance from local agencies ... The local agents that appear inside of the national ... fast method of price reviews this year. Adults who ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 AVEC ... to announce the addition of Kerry Gillespie as ... of healthcare management experience, Gillespie brings an extremely ... multiple executive management positions with prominent industry leading ... served as President of Triad Isotopes, Inc. a ...
Breaking Medicine News(10 mins):Health News:Cincinnati’s New Troubled Teen Helpline is Making a Difference in the Community 2Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 2Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 3Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 4Health News:4 Skincare Products That Boost and Nurture Collagen on Sale at Sublime Beauty® 2Health News:4 Skincare Products That Boost and Nurture Collagen on Sale at Sublime Beauty® 3Health News:Life Insurance from Local Agents Now Priced Nationally Through Complimentary Tool Online 2Health News:Kerry Gillespie Appointed as Chief Executive Officer of AVEC Health Solutions 2
... campuses of the University of California has found that flash-heating ... virus. ,The researchers hope that this technique - ... pan of water over a flame or single burner - ... nations will soon be able to more safely feed their ...
... rigorous U.S. trial comparing two traditional operations for stress ... urologists and urogynecologists supported by the National Institutes of ... more women achieve dryness than the Burch technique. ... a meticulous, relatively long-term comparison of these common surgeries ...
... given people another reason to quit smoking, by finding that ... depression in comparison to those who never smoke. ,The ... an elevated risk of depressive symptoms in short run, this ... long run. ,In other words, both completely ...
... Well, it doesnt have to be that way ... say that they have successfully managed to reduce ... containing vitamin A. ,Not only did the ... 23 people revealed it boosted levels of important skin ...
... a condition that most people prefer not to talk about, ... this embarrassing problem. It's called overactive bladder (OAB) and ... sometimes causing urine leakage. ,Now, to reduce the ... using nerve stimulation in the ankle to better help control ...
... chronic gum disease periodontitis, may have an increased risk of ... ,Periodontitis is an oral infection thought to be caused by ... well. ,The study was conducted by a team ... of New York at Buffalo and the Roswell Park Cancer ...
Cached Medicine News:Health News:Flash-heating Inactivates HIV in Breast Milk: Study 2Health News:Flash-heating Inactivates HIV in Breast Milk: Study 3Health News:Sling Surgery Better Than Burch for Treating Stress Incontinence in Women 2Health News:Sling Surgery Better Than Burch for Treating Stress Incontinence in Women 3Health News:Regular Smokers are at the Risk of Developing Depression 2Health News:Wrinkles can Be Really Ironed Out, Thanks to Vitamin A 2Health News:Stimulating the Ankle Can Help Patients With Overactive Bladder 2Health News:Men With Chronic Gum Disease at Higher Risk of Tongue Cancer 2
... take the words "mobile operating table" literally! The ... important functions of a general purpose operating table ... For table operations, a cable connected hand control, ... available. Plus, there is a control panel at ...
... carbon fiber c-arm table allows 50 ... brachytherapy, gynecology, gastroenterology, cardiovascular, orthopedic, ENT, ... design allows easy access for all ... 16-inch elevating travel, 16-inch longitudinal travel, ...
... for procedures where stability, access, and ... A cantilevered low attenuation carbon fiber ... The radiolucent area is free of ... and unobstructed C-Arm positioning. Functional design ...
... Lyphochek Elevated Immunosuppressant Control is a bilevel ... blood. This unique product is ideal for ... high Cyclosporine levels, such as C2 monitoring, ... at two hours post-dose., ,Lyphochek Elevated Immunosuppressant ...
Medicine Products: